USA flag logo/image

An Official Website of the United States Government

TOPICAL PRODRUGS FOR TREATMENT OF ACNE AND SKIN DISEASES

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
2956 		Program Year/Program:
1987 / SBIR
Agency Tracking Number:
2956 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
MOLECULAR DESIGN INTERNATIONAL, INC.
111 South Highland Street MEMPHIS, TN 38111-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1987
Title: TOPICAL PRODRUGS FOR TREATMENT OF ACNE AND SKIN DISEASES
Agency: HHS
Contract: N/A
Award Amount: $263,000.00
 

Abstract:

THE LONG-TERM OBJECTIVE OF THIS PROJECT IS TO DEVELOP A COMMERCIAL PRODUCT FOR THE TOPICAL TREATMENT OF ACNE AND SKIN DISEASES. THE SPECIFIC AIM OF THE PROPOSAL IS TO INVENT A PRODRUG THAT CAN BE USED EFFECTIVELY AND SAFELY FOR THE TOPICAL TREATMENT OF ACNE. SINCE ISOTRETINOIN (13-CIS-RETINOIC ACID, ACCUTANE-ROCHE) ADMINISTERED ORALLY CAUSES BIRTH DEFECTS AND APPLIED TOPICALLY IS IRRITATING, WE HAVE DESIGNED PRODRUGS OF ISOTRETINOIN. THESE PRODRUGS ARE INTENDED 1.TO BE APPLIED TOPICALLY, 2.TO MAKE ISOTRETINOIN BIOAVAILABLE AT THE TARGET SITE BY HYDROLYSIS OF THE PRODRUG IN THE SKIN, AND THREE PRODRUGS HAVE ALREADY BEEN SYNTHESIZED AND TESTED IN THE TOPICAL RHINO MOUSE ASSAY AND THE ORAL HAMSTER SEBACEOUS GLAND ASSAY. ONE OF OUR COMPOUNDS, MDI 3831101, IS AS EFFECTIVE AS ISOTRETINOIN IN THE SAME ASSAYS. SINCE THIS IS A NEW COMPOUND, A PATENT APPLICATION HAS BEEN FILED.WE PROPOSE TO SYNTHESIZE ADDITIONAL SAMPLES OF MDI 3831101 AND ADDITIONAL PRODRUGS OF ISOTRETINOIN IN ORDER TO OPTIMIZE OUR LEAD COMPOUND.

Principal Investigator:

Harlie A. Parish
Principal Investigator
9014541919

Business Contact:

Small Business Information at Submission:

Molecular Design International
P.o. Box 41777 Memphis, TN 38174

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No